Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
McGill, industry, CQDM and Brain Canada collaborate for drug discovery
Details : The funding aims to advance the discovery of investigational products that have made significant progress in development and could help treat insomnia and neuropathic pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 07, 2024
Lead Product(s) : Coenzyme Q10,Caspofungin
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Sponsor : Clarus
Deal Size : $40.8 million
Deal Type : Licensing Agreement
Details : Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).
Product Name : Ubiquinone
Product Type : Enzyme
Upfront Cash : $0.4 million
September 16, 2021
Lead Product(s) : Coenzyme Q10,Caspofungin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Sponsor : Clarus
Deal Size : $40.8 million
Deal Type : Licensing Agreement